Chemoradiation Treatment for Head and Neck Cancer
TROG 07.04 A Phase I/II Study of Cetuximab, Carboplatin and Radiotherapy for patients with locally advanced head and neck squamous cell carcinoma
Trans Tasman Radiation Oncology Group
60 participants
Apr 30, 2008
Interventional
Conditions
Summary
This is a Phase II study of cetuximab, carboplatin and radiotherapy (RT) in patients with Locally Advanced Head and Neck Carcinomas (LAHNC) who are unfit for cisplatin. The aim of this study is to show the feasibility and safety profile of the combination of cetuximab, carboplatin and RT in treatment of patients with LAHNC.
Eligibility
Inclusion Criteria22
- Previously untreated Squamous Cell Carcinoma (SCC) of the oropharynx, larynx or hypopharynx.
- Stage III or IV, excluding T1N1, and metastatic disease (to be confirmed by a chest CT, and abdominal CT or ultrasound scan if patients with abnormal liver function tests or a bone scan or Flurodeoxyglucose Positron Emission Tomography (FDG-PET) if patients with bone pain).
- Histologically or cytologically confirmed Head and Neck SCC
- Disease must be considered potentially curable by chemoradiation
- Patients medically unfit for cisplatin chemotherapy due to one or more of the following reasons:
- Clinically significant sensori-neural hearing impairment (audiometric abnormalities without corresponding clinical deafness will not be regarded as a contraindication to cisplatin)
- Severe tinnitus
- Renal impairment (Glomerular Filtration Rate (GFR) < 60ml/min)
- Peripheral neuropathy > grade 2
- Inability to tolerate intravenous hydration eg due to cardiac disease
- Co-morbidities (based on clinical judgement by the investigator) associated with Eastern Cooperative Oncology Group Performance Status (ECOG PS) 2 that in the view of the investigator would preclude the safe administration of cisplatin
- Performance status ECOG 0, 1 or 2.
- Adequate haematological, renal and hepatic functions as defined by:
- Absolute neutrophil count (Absolute Neutrophil Count (ANC), segmented cells (segs) + bands)>= 1.5 x 109/L
- Platelet count >= 100 x 109/L
- Total bilirubin <= 1.5 x upper normal limit
- Alanine aminotransferase <= 2.5 x upper normal limit
- Calculated creatinine clearance > 40ml/min (Cockcroft-Gault formula).
- If calculated creatinine clearance < 50 ml/min, glomerular filtration rate to be measured with Diethylene triamine pentaacetic acid (DTPA) or Ethylenediaminetetraacetic acid (EDTA) scan. If < 40 ml/min not eligible.
- Age >18 years
- Signed written consent
- Suitable for follow-up for 4 years in the view of the investigator
Exclusion Criteria12
- Distant metastases, i.e., any metastatic disease below the clavicles. Patients with lung nodules >10mm will be excluded unless non-malignancy aetiology is established. Patients with lesions 5-10mm can be included if a flurodeoxyglucose positron emission tomography (FDG-PET) scan is negative and the investigator considers on clinical grounds that metastasis is unlikely. Patients with lesions < 5mm can be included if the investigator considers on clinical grounds that metastases are unlikely. Patients with multiple lung nodules should not be included unless there is a strong case that these do not represent metastases, e.g., stable on imaging for over 12 months, non-malignant aetiology apparent. The level of clinical suspicion may be influenced by clinical stage, e.g., N3 disease, low neck nodes. In general if there is any doubt patients should be excluded.
- Previous radical radiotherapy (RT) to the head & neck region, excluding superficial RT for a non-melanomatous skin cancer.
- Patients with prior cancers, except: those diagnosed > 5 years ago with no evidence of disease recurrence and clinical expectation of recurrence of less than 5%; or successfully treated non-melanoma skin cancer; or carcinoma in situ of the cervix.
- Significant intercurrent illness that will interfere with the chemotherapy or radiation therapy such as Humman Immunodeficiency virus (HIV) infection, cardiac failure, pulmonary compromise, active infection
- Any history of myocardial infarction, ventricular arrhythmias, or unstable angina within the last 6 months
- Pregnant or lactating women.
- Weight loss greater than 20 % of usual body weight in the 3 months preceding trial entry
- High risk for poor compliance with therapy or follow up as assessed by the investigator
- Prior radiation to greater than 30% of the bone marrow
- Prior systemic chemotherapy for cancer
- Refusal by male or female patients, to use appropriate contraception during the study and for 3 months afterwards
- Any condition or circumstance which might prevent the patient being able to give valid informed consent, or from completing participation in the study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
1. Cetuximab. Patients will receive weekly intravenous cetuximab (initial dose 400mg/m2 in the week prior to commencing radiotherapy, then weekly 250mg/m2)for the duration of the radiotherapy 2. Carboplatin. Weekly intravenous carboplatin (Area Under the Curve (AUC) 2) for the duration of the radiotherapy 3. Radiotherapy. The radiotherapy schedule will be the "infield boost" (IFB) regimen, that is 66 Gy in 35 fractions over 5 weeks: daily for 3 weeks, then twice daily for 2 weeks (or 70 Gy in 35 fractions over 7 weeks - 5fractions/ week - for a specific subgroup of patients where IFB is not recommended).
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12613000695707